van Breemen, Richard B <br/><br/>
How do intermediate endpoint markers respond to lycopene in men with prostate cancer or benign prostate hyperplasia?  [electronic resource] 

 -  The Journal of nutrition  Aug 2005 
 - 2062S-4S p.  digital 
<br/><br/> Publication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0022-3166 
<br/><br/><label>Standard No.: </label>10.1093/jn/135.8.2062S  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Anticarcinogenic Agents--therapeutic use<br/>Biomarkers--blood<br/>Carotenoids--therapeutic use<br/>Humans<br/>Lycopene<br/>Male<br/>Placebos<br/>Prostate-Specific Antigen--blood<br/>Prostatic Hyperplasia--blood<br/>Prostatic Neoplasms--pathology<br/>Reproducibility of Results